Semaglutide | 910463-68-2

Semaglutide, a long-acting GLP-1 analogue, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide has the potential for type 2 diabetes treatment.

Semaglutide is a polypeptide that contains a linear sequence of 31 amino acids joined together by peptide linkages. It is an agonist of glucagon-like peptide-1 receptors (GLP-1 AR) and used for the treatment of type 2 diabetes. It has a role as a hypoglycemic agent, a glucagon-like peptide-1 receptor agonist, an anti-obesity agent, a neuroprotective agent and an appetite depressant. It is a polypeptide and a lipopeptide.

Name Semaglutide	Molecular structural formula
Purity ≥98%
CAS Number 910463-68-2
Formula C187H291N45O59
MW 4113.64
Pharmacology Semaglutide is a drug molecule that mimics GLP-1, a naturally occurring hormone in the human body, and has 94% sequence homology with the latter. GLP-1 is one of many hormones released by the small intestine after people eat. It can promote the secretion of insulin when it acts on the pancreas, slow down gastric emptying when it acts on the digestive tract, and produce a feeling of fullness when it acts on the hypothalamus. Therefore, drugs that mimic GLP-1 (such as semaglutide) can activate GLP-1 receptors in the human body, which not only regulates blood sugar and treats diabetes, but also slows digestion and suppresses appetite. Not only that, semaglutide is more stable than GLP-1 in the human body and can be effective when used once a week.
Indications Treat type 2 diabetes; Lose weight; Improve metabolic health; Lower cholesterol levels
Contraindications pregnant woman type 1 diabetes Patients with diabetic ketoacidosis, medullary thyroid cancer and related family history, etc.
Route of administration subcutaneous injection, oral administration
Target GCGR
Sequence His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-{C18 diacid-gamma-Glu-(AEEA)2-Lys}-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Sequence Shortening H-{Aib}-EGTFTSDVSSYLEGQAA-{C18 diacid-γ-Glu-(AEEA)2-Lys}-EFIAWLVRGRG
InChIKey DLSWIYLPEUIQAV-CCUURXOWSA-N
Solubility in DMSO < 1 mg/mL
Solubility in water 22.22 mg/mL
References [1]. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. [2]. Zhang L, et al. Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model. Neuropeptides. 2018 Oct;71:70-80. [3]. Dhillon S, et al. Semaglutide: First Global Approval. Drugs. 2018 Feb;78(2):275-284.